Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11241416 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
US10987341 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
US11478450 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) | |
US11826352 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | May 12, 2025 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis
Dosage: SUSPENSION;ORAL